- Home
- XP vs LNTH Comparison
XP vs LNTH Comparison
Compare XP & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XP
- LNTH
- Stock Information
- Founded
- XP 2001
- LNTH 1956
- Country
- XP Cayman Islands
- LNTH United States
- Employees
- XP N/A
- LNTH N/A
- Industry
- XP Investment Bankers/Brokers/Service
- LNTH Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- XP Finance
- LNTH Health Care
- Exchange
- XP Nasdaq
- LNTH Nasdaq
- Market Cap
- XP 6.0B
- LNTH 6.3B
- IPO Year
- XP 2019
- LNTH 2015
- Fundamental
- Price
- XP $11.41
- LNTH $94.05
- Analyst Decision
- XP Buy
- LNTH Strong Buy
- Analyst Count
- XP 7
- LNTH 6
- Target Price
- XP $23.57
- LNTH $132.67
- AVG Volume (30 Days)
- XP 6.8M
- LNTH 723.3K
- Earning Date
- XP 02-25-2025
- LNTH 02-20-2025
- Dividend Yield
- XP 5.70%
- LNTH N/A
- EPS Growth
- XP 19.15
- LNTH 304.57
- EPS
- XP 1.46
- LNTH 6.02
- Revenue
- XP $2,917,445,096.00
- LNTH $1,496,799,000.00
- Revenue This Year
- XP $24.67
- LNTH $19.64
- Revenue Next Year
- XP $13.88
- LNTH $5.16
- P/E Ratio
- XP $8.23
- LNTH $15.62
- Revenue Growth
- XP 18.63
- LNTH 24.15
- 52 Week Low
- XP $10.82
- LNTH $50.20
- 52 Week High
- XP $26.78
- LNTH $126.89
- Technical
- Relative Strength Index (RSI)
- XP 35.36
- LNTH 53.53
- Support Level
- XP $11.00
- LNTH $89.92
- Resistance Level
- XP $12.15
- LNTH $97.25
- Average True Range (ATR)
- XP 0.44
- LNTH 3.42
- MACD
- XP 0.17
- LNTH 0.05
- Stochastic Oscillator
- XP 44.53
- LNTH 67.86
About XP XP Inc.
XP Inc is a Cayman Island-based technology-driven financial services platform. It is a provider of low-fee financial products and services in Brazil. The company evaluates its business through a single segment such as monitoring operations, making decisions on fund allocation, and evaluating the performance. It generates revenue through the Brokerage commission.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.